[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Kumar M, Bahl A, Sharma DN, Sharma R, Gupta R, Ahmed S, Julka PK, Rath GK: Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma. J Cancer Res Ther; 2009 Apr-Jun;5(2):124-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma.
  • Cylindric cell carcinomas (transitional cell carcinomas) are a rare and distinct histopathological entity presenting in the head and neck region.
  • They have been known by myriads of nomenclature like cylindric carcinomas, nonkeratinizing sinonasal carcinoma, papillary carcinoma, cylindrical or columnar cell carcinoma, intermediate cell carcinoma, Schneiderian carcinoma, and Ringertz carcinoma.
  • They are considered a variant of nonkeratinizing squamous cell carcinoma.
  • Only passing references have been made for its presentation in oropharynx including tonsils and the base of the tongue.
  • We report here a rare case of transitional cell carcinoma presenting in the base of the tongue.
  • There are no separate treatment recommendations in the literature, and the management is on the lines of treatment of squamous cell carcinoma.
  • We report here a case of cylindric cell carcinoma presenting in the base of the tongue.
  • The patient received palliative radiotherapy of 20 Gy in five fractions followed by chemotherapy with injection paclitaxel and carboplatin.
  • A partial response to treatment was achieved at the time of writing this report.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542670.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Wang HM, Wang CS, Chen JS, Chen IH, Liao CT, Chang TC: Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer; 2002 Jun 1;94(11):2989-95
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin, tegafur, and leucovorin: a moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
  • BACKGROUND: To evaluate the efficacy and toxicity of cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy (CT) for patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).
  • PTL was initiated with the intent of organ preservation and it was continued for a maximum of six cycles before locoregional therapy.
  • The primary tumor sites were the tongue base, 14, and the hypopharynx, 83.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Ambulatory Care Facilities. Cisplatin / administration & dosage. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Tegafur / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12115388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  •  go-up   go-down


3. Jo S, Juhasz A, Zhang K, Ruel C, Loera S, Wilczynski SP, Yen Y, Liu X, Ellenhorn J, Lim D, Paz B, Somlo G, Vora N, Shibata S: Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. Anticancer Res; 2009 May;29(5):1467-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.
  • The aim of this study was to determine the presence of high-risk HPV-16 in patients with HNSCC, assess the impact of HPV status on treatment response and survival in this select cohort treated with combined modality therapy and to identify the differences in HIF-1alpha and VEGF expression in HPV-positive and -negative tumors.
  • PATIENTS AND METHODS: Patients had resectable, untreated stage III, IV HNSCC of the oral cavity, oropharynx, hyopharynx or larynx, and stage II cancer of the base of tongue, hypopharynx and larynx.
  • HIF-1alpha and VEGF expression were assessed by quantitative real-time PCR (RT-PCR).
  • There were no significant differences in response rates after neoadjuvant chemotherapy (86% vs. 90%) in HPV-positive and HPV-negative patients, respectively.
  • CONCLUSION: HPV presence portended a better prognosis in patients with oropharyngeal SCC treated with a multimodality treatment in a prospective clinical trial.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Surg. 1983 Dec;12(6):418-24 [6325356.001]
  • [Cites] EMBO J. 1988 Jun;7(6):1815-20 [2458921.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):153-9 [11943893.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jul;125(1):1-9 [11458206.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):401-3 [11328843.001]
  • [Cites] Oncogene. 2000 Sep 21;19(40):4611-20 [11030150.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):300-4 [10861508.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):117-23 [10585594.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2568-76 [17473185.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1418-25 [17205528.001]
  • [Cites] Cell Mol Life Sci. 2006 Apr;63(7-8):930-8 [16596339.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2558-64 [16314836.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):206-13 [15790460.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):775-82 [10213212.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):755-62 [9816227.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):145-56 [9422532.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):513-6 [9158399.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):595-604 [9028373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3187-92 [12374687.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2620-6 [12855639.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):394-400 [14506739.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):766-72 [14696105.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):468-71 [14744758.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):418-23 [15091212.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006 [15240783.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3061-9 [15284256.001]
  • (PMID = 19443352.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers
  • [Other-IDs] NLM/ NIHMS431020; NLM/ PMC3582681
  •  go-up   go-down


Advertisement
4. Diaz R, Blakey MD, Murphy PB, Cryar AK, Cmelak AJ: Thyroid storm after intensity-modulated radiation therapy: a case report and discussion. Oncologist; 2009 Mar;14(3):233-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid storm after intensity-modulated radiation therapy: a case report and discussion.
  • A 43-year-old man with locally advanced squamous cell carcinoma of the base of tongue was treated with induction chemotherapy followed by intensity-modulated radiation therapy (IMRT).
  • Within 20 days post-treatment, the patient developed clinical symptoms highly suggestive of hyperthyroidism.
  • Two and one half months after completion of therapy, the patient developed severe thyrotoxicosis, which, in retrospect, appears to have met the criteria for thyroid storm.
  • This case history illustrates a previously unreported, life-threatening complication of external-beam radiation that should be considered in patients receiving IMRT therapy involving the thyroid.
  • Diagnosis of the patient's hyperthyroidism and probable thyroid storm was difficult to recognize because of the significant overlap between the signs and symptoms of severe thyrotoxicosis and the expected toxicities of his cancer therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Thyroid Crisis / etiology. Tongue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Radiotherapy, Intensity-Modulated / adverse effects. Thyroid Hormones / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286762.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thyroid Hormones
  •  go-up   go-down


5. Logemann JA, Rademaker AW, Pauloski BR, Lazarus CL, Mittal BB, Brockstein B, MacCracken E, Haraf DJ, Vokes EE, Newman LA, Liu D: Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck; 2006 Jan;28(1):64-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation.
  • BACKGROUND: The relationship between type of chemoradiation treatment, site of disease, and swallowing function has not been sufficiently examined in patients with head and neck cancer treated primarily with chemoradiation.
  • METHODS: Fifty-three patients with advanced-stage head and neck cancer were evaluated before and 3 months after chemoradiation treatment to define their swallowing disorders and characterize their swallowing physiology by site of lesion and chemoradiation protocol.
  • RESULTS: The most common disorders at baseline and 3 months after treatment were reduced tongue base retraction, reduced tongue strength, and slowed or delayed laryngeal vestibule closure.
  • Frequency of functional swallow did not differ significantly across disease sites after treatment, although frequency of disorders was different at various sites of lesion.
  • The effects of the chemotherapy protocols were small.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deglutition Disorders / etiology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Deglutition / drug effects. Deglutition / physiology. Deglutition / radiation effects. Female. Humans. Male. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. Head Neck 27: XXX-XXX, 2005.
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jan;24(1):68-77 [11774405.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):320-6 [12525525.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1689-97 [12738722.001]
  • [Cites] Head Neck. 2003 Jun;25(6):432-7 [12784234.001]
  • [Cites] Gastrointest Radiol. 1983;8(2):97-104 [6343174.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 May;14(5):839-48 [3360653.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):711-6 [3138220.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] Rev Stomatol Chir Maxillofac. 1989;90(5):334-6 [2799248.001]
  • [Cites] Dysphagia. 1991;6(2):120-2 [1935259.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):419-22 [7977964.001]
  • [Cites] Laryngoscope. 1996 Sep;106(9 Pt 1):1157-66 [8822723.001]
  • [Cites] Head Neck. 1999 Oct;21(7):595-601 [10487945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87 [10524409.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Mar;109(3):320-5 [10737318.001]
  • [Cites] Head Neck. 2000 Aug;22(5):474-82 [10897107.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1961-9 [11283128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Int J Cancer. 2001;96 Suppl:61-70 [11992387.001]
  • (PMID = 16302193.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA040007; United States / NIDCR NIH HHS / DE / P50 DE011921
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS7896; NLM/ PMC1380204
  •  go-up   go-down


6. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M: Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg; 2003 Jan;129(1):36-43
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue.
  • OBJECTIVE: To determine the role of transoral laser microsurgery for base of tongue squamous cell carcinoma.
  • DESIGN: Retrospective unicenter study of the oncologic and functional results of laser microsurgery of tongue base carcinoma performed between 1986 and 1997.
  • PATIENTS: We reviewed 48 previously untreated patients with base of tongue squamous cell carcinoma, who were treated with transoral laser microsurgery.
  • Selective neck dissection was performed in 43 patients; 23 patients underwent postoperative radiotherapy with or without simultaneous chemotherapy.
  • Twenty-one patients survived at least 5 years after treatment.
  • CONCLUSIONS: Our concept of organ and function preserving laser microsurgery for selected patients with base of tongue cancer seems to be justified considering the achieved oncological and functional results.
  • Final proof of the effectiveness of the new therapeutic concept presented herein requires well-designed prospective studies.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laser Therapy. Tongue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525192.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Hancock SB, Krempl GA, Canfield V, Bogardus C, Kojouri K, Kaneaster SK, Medina JE: Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy. Laryngoscope; 2008 Aug;118(8):1357-61
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
  • OBJECTIVES/HYPOTHESIS: To assess the efficacy of paclitaxel, ifosfamide, and cisplatinum induction chemotherapy plus concurrent chemoradiation in the treatment of stage III and IV base of tongue cancer.
  • STUDY DESIGN: Subgroup analysis of patients with base of tongue cancer enrolled in a single-institution prospective phase II trial, evaluating an organ-preservation approach in the treatment of locally advanced head and neck cancer.
  • METHODS: Eighteen patients with tumors ranging from stage T2-T4, any N, or M0 were treated with a protocol of induction chemotherapy, with Taxol, ifosfamide, cisplatin every 21 days for up to three cycles.
  • Neck dissection was performed in cases with clinical or radiological evidence of persistent disease in the neck 6 to 8 weeks after completion of treatment.
  • Only 1 of them developed distant metastases 30 months after completion of treatment.
  • CONCLUSIONS: The treatment regimen studied is remarkably effective in stage III and IV base of tongue cancer with 100% of patients completing the protocol alive to date.
  • Although some patients required persistent percutaneous endoscopic gastrostomy use, no patient experienced significant enough toxicity during the protocol to delay or withdraw from treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Tongue Neoplasms / drug therapy. Tongue Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Tongue cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18528311.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


8. Jegannathen A, Swindell R, Yap B, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N: Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Clin Oncol (R Coll Radiol); 2010 Apr;22(3):185-91
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer?
  • AIM: To evaluate the tolerability of synchronous chemotherapy and accelerated hypofractionated radiotherapy in patients with locally advanced squamous cell carcinoma of the base of the tongue.
  • MATERIALS AND METHODS: Between 1999 and 2004, 43 patients with stage II-IV squamous cell carcinoma of the base of the tongue were treated with a combined modality of radiotherapy (prescribed 55 Gy in 20 fractions), synchronous chemotherapy and in some cases surgical neck dissection.
  • End points were acute and late toxicity, 3 year locoregional control, overall survival, cancer-specific survival and compliance.
  • All patients completed radiotherapy and 30% received neoadjuvant chemotherapy.
  • The median time for the completion of treatment was 27 days (range 25-36).
  • Overall, only 42% completed the prescribed synchronous chemotherapy.
  • However, compliance increased to 60% in patients who did not receive neoadjuvant chemotherapy.
  • Grade 3 mucositis developed in 90% of patients.
  • Prolonged grade 3 mucositis (>4 weeks) was seen in 24/43 (56%) and none developed grade 4 mucositis.
  • The 3 year locoregional control, overall survival and cancer-specific survival were 70, 60 and 60%, respectively.
  • Clinical T staging was most significantly associated with poor overall survival, cancer-specific survival and local control.
  • CONCLUSION: The addition of synchronous chemotherapy to accelerated hypofractionated radiotherapy consistently led to grade 3 mucositis.
  • Higher mucosal toxicity and lower synchronous chemotherapy compliance compared with other series may suggest that this approach is at the limit of patient tolerability.
  • However, the tumour site investigated and the choice of synchronous chemotherapy agent may also be important.
  • Longer fractionation will probably increase compliance with chemotherapy, particularly when induction is used before synchronous treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / therapy. Radiotherapy / methods. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Tongue cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20116980.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Finnegan V, Parsons JT, Greene BD, Sharma V: Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma. Head Neck; 2009 Feb;31(2):167-74
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
  • BACKGROUND: Radiation therapy (RT) is commonly used in the management of patients with advanced (T3-T4) oropharyngeal squamous cell carcinomas.
  • In recent years, based upon the meta-analyses of randomized trials, chemotherapy administered concurrently with RT (chemoradiotherapy) has become the standard of care.
  • Concurrent chemotherapy administered along with hyperfractionated or accelerated RT has been shown to add significant additional benefit over hyperfractionated or accelerated RT alone.
  • Neoadjuvant chemotherapy (usually consisting of cisplatin and fluorouracil) also produces favorable responses in most patients (approximately 75% partial or complete response rates) with advanced head and neck cancer, but its role remains controversial.
  • METHODS: The results of treatment of 23 patients with T3 or T4 oropharyngeal squamous cell carcinomas who received neoadjuvant chemotherapy, followed by hyperfractionated RT (120 cGy twice-a-day to 74.4-76.8 Gy) were retrospectively reviewed.
  • The 14 patients who were most recently treated also received concurrent sensitizing doses of single agent chemotherapy, usually cisplatin.
  • Ten patients had base of tongue primaries, 12 had tonsillar primaries, and 1 had an oropharyngeal wall primary.
  • RESULTS: Seventy-four percent of patients had partial (>50%) or complete response at the primary site following neoadjuvant chemotherapy.
  • Four patients developed neck failure after RT alone and none was successfully salvaged.
  • CONCLUSION: This study is noteworthy in that it uses both neoadjuvant and concurrent sensitizing chemotherapy along with hyperfractionated RT.
  • Although the regimen is somewhat toxic, it is less so than many other regimens, which combined full-dose multiagent chemotherapy during the course of RT.
  • We continue to recommend this regimen for patients with locally advanced head and neck squamous cell carcinomas.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / therapy. Dose Fractionation. Neoadjuvant Therapy. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cohort Studies. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853443.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Shin HA, Lim YC, Jeong HM, Choi EC: Role of primary surgery for early-stage (T1-2N0) squamous cell carcinoma of the oropharynx. Oral Oncol; 2009 Dec;45(12):1063-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of primary surgery for early-stage (T1-2N0) squamous cell carcinoma of the oropharynx.
  • To evaluate treatment outcomes and the role of primary definitive surgery for T(1-2), clinically N(0) oropharyngeal squamous cell carcinoma (OPSCC) patients, we performed a retrospective analysis of 46 consecutive cases treated primarily by surgery and/or postoperative radiotherapy at Yonsei University between May 1992 and December 2006.
  • The most common location was the tonsil (54%), followed by the soft palate (19%), the base of the tongue (BOT) (15%) and the posterior wall (12%).
  • Almost 30% of all patients may be candidates for adjuvant chemotherapy through histopathologic analysis according to the National Comprehensive Cancer Network (2007) guidelines.
  • The results of the present study demonstrate excellent oncologic outcomes with primary surgery for the treatment of early-stage OPSCC and suggest that surgery offers the best opportunity to identify patients in whom adjuvant radio- or chemotherapy may be most appropriately applied.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Republic of Korea. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19717331.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Homma A, Suzuki F, Oridate N, Furuta Y, Inuyama Y, Fukuda S: [Long-term complete response to treatment with TS-1 in a patient with oropharyngeal squamous cell carcinoma]. Gan To Kagaku Ryoho; 2002 Aug;29(8):1475-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term complete response to treatment with TS-1 in a patient with oropharyngeal squamous cell carcinoma].
  • A 60-year-old man had a recurrence of squamous cell carcinoma at the right side of the tongue base.
  • Chemotherapy with TS-1 (100 mg/day) was begun.
  • Each course of chemotherapy consisted of 4 weeks of TS-1, followed by 2 weeks of no treatment.
  • From the third course of TS-1 treatment, the dose was increased to 120 mg/day.
  • A biopsy done during the ninth course of TS-1 treatment confirmed the complete response histologically, with no evidence of malignancy.
  • After 12 courses of TS-1 treatment, the drug was switched to 600 mg/day of UFT.
  • Although there were no signs or symptoms of recurrence, the patient died of cancer of the pancreas.
  • There was no recurrence of the oropharyngeal cancer, even at the time of death.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Oropharyngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Humans. Male. Middle Aged. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214481.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


12. Simon C, Goepfert H, Rosenthal DI, Roberts D, El-Naggar A, Old M, Diaz EM Jr, Myers JN: Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival. Eur Arch Otorhinolaryngol; 2006 Apr;263(4):313-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of malignant tumor cells in persistent neck disease after radiotherapy for advanced squamous cell carcinoma of the oropharynx is associated with poor survival.
  • Non-surgical therapy consisting of external beam radiation with or without chemotherapy is an effective treatment for patients with squamous cell carcinoma (SCC) of the oropharynx with advanced neck disease (N2a or greater).
  • In order to address the significance of this finding, we conducted a nonrandomized retrospective study, including 35 patients who underwent definitive radiation therapy followed by either a radical or modified radical (RND/MRND) or a selective neck dissection (SND) for clinically persistent neck disease 6 weeks after completing therapy for stage III/IV SCC of the oropharynx (base of the tongue =15, tonsil =12, soft palate =7 and pharyngeal wall =1).
  • We observed an increased relative risk (RR) for local and regional failures in the patient population with viable cancer cells in the post-irradiation neck specimens (RR=6.7 and 4.1, respectively).
  • In conclusion, the presence of viable cancer cells in radiated neck nodes is a novel prognostic marker for disease-specific survival in patients treated for SCCs of the oropharynx with advanced neck disease and may serve as an identifier for patients who will benefit from post-treatment chemoprevention.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cell Survival. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm, Residual. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):737-42 [1618666.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):724-9 [6693288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):657-62 [2493434.001]
  • [Cites] Semin Radiat Oncol. 1992 Jul;2(3):163-170 [10717032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):289-96 [8567328.001]
  • [Cites] Laryngoscope. 2000 Dec;110(12):2074-80 [11129024.001]
  • [Cites] Am J Surg. 1972 Oct;124(4):462-7 [5076159.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Head Neck. 2002 May;24(5):474-81 [12001078.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):401-6 [9559686.001]
  • [Cites] Head Neck. 2003 Nov;25(11):960-7 [14603457.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2967-80 [12115386.001]
  • [Cites] Head Neck. 1998 Mar;20(2):132-7 [9484944.001]
  • [Cites] CA Cancer J Clin. 2004 May-Jun;54(3):150-80 [15195789.001]
  • [Cites] Head Neck. 1999 Oct;21(7):606-13 [10487947.001]
  • (PMID = 16328403.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Khalid AA, Morgan JE, Horace S, Hanna EY, Breau R, Kyasa MJ, Maddox AM: Early complications of organ preservation treatment in head and neck cancer, UAMS experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):5607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early complications of organ preservation treatment in head and neck cancer, UAMS experience.
  • : 5607 Background Patients undergoing organ preservation treatment (chemotherapy/radiation therapy) for squamous cell cancer of the head and neck (SCCHN) develop many early complications.
  • Methods Retrospective analysis of patients undergoing organ preservation treatment for SCCHN at UAMS from 10-92 through 8-02.
  • Most common site was base of tongue (20.41%) followed by larynx (17.69%).Median age at diagnosis was 58 yrs.
  • Grade I renal insufficiency was 21%, grade II 3.7% and grade III in 3.7%.PEG was placed prior to treatment in 78(60%) of patients, 18 (13.85%) during treatment, 28 (21.54%) did not receive PEG.
  • There was no statistically significant difference in the median LOS of patients who received PEG prior to treatment and those who received PEG during treatment.
  • Conclusions Organ preservation treatment of SCCHN is associated with tolerable early complications including mucositis, neutropenia, renal impairement and wt loss often requiring hospitalization for management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015296.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Shibata S, Paz B, Ellenhorn J, Vora N, Somlo G, Koczywas M, Lim D, Frankel P, Wagman L, Doroshow J: A phase II trial of neoadjuvant chemotherapy (NCT), organ-sparing surgery, and radiation in squamous cell head and neck cancer (SCHNC): Results of neoadjuvant chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):5617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of neoadjuvant chemotherapy (NCT), organ-sparing surgery, and radiation in squamous cell head and neck cancer (SCHNC): Results of neoadjuvant chemotherapy.
  • : 5617 Background: NCT with radiation has facilitated organ-sparing treatment in locally advanced SCHNC.
  • METHODS: Pts had resectable untreated stage III, IV SCHNC of the oral cavity, oropharynx, hyopharynx, or larynryx, and stage II cancer of the base of tongue, hypopharynx, and larynx.
  • PCR was seen in 15/18 primary sites, and no pt required laryngectomy or base of tongue resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015276.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kljajić V, Jović R, Canji K, Nikolin B, Gavrilović M: [Surgical techniques and outcomes in the treatment of malignant tongue base tumors]. Med Pregl; 2007 Jan-Feb;60(1-2):49-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical techniques and outcomes in the treatment of malignant tongue base tumors].
  • INTRODUCTION: Prognosis of patients with malignant tongue base tumors is poor.
  • Survival is low, in spite of different treatment modalities.
  • Most patients seek treatment too late, when their disease has already progressed to stage III or IV.
  • The aim of this investigation was to compare different treatment modalities in patients with malignant tongue base tumors.
  • Planocellular cancer was diagnosed in 79/82 patients, and the remaining (3182) had transitional cell carcinoma.
  • Surgical treatment alone was performed in 17 patients, seven were treated with radiation only, and nine only with chemotherapy.
  • Combined surgical and radiation therapy was performed in 28 patients, and 5 were treated with all three.
  • Ten patients were not treated with any therapy.
  • Tongue base resection only was performed in 12 patients, tongue base resection with epiglottectomy in 20, tongue base resection with supraglottic laryngectomy in 13 and tongue base resection with total laryngectomy in 5 patients.
  • Five-year survival after combined surgical and radiation therapy was 35% CONCLUSION: Development of tongue base carcinoma is strongly associated with alcohol and tobacco consumption.
  • Survival is low, despite various treatment modalities.
  • However, combined therapy is the therapy of choice in cases with tongue base carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Tongue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853711.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


17. Weinstein GS, Quon H, O'Malley BW Jr, Kim GG, Cohen MA: Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: a subset analysis of the University of Pennsylvania transoral robotic surgery trial. Laryngoscope; 2010 Sep;120(9):1749-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: a subset analysis of the University of Pennsylvania transoral robotic surgery trial.
  • OBJECTIVES/HYPOTHESIS: The purpose of this study was to determine the regional recurrence rate of node-positive oropharyngeal squamous cell carcinoma (OPSCC) in patients undergoing transoral robotic surgery (TORS) and selective neck dissection (SND) followed by observation, radiation, or concurrent chemoradiation.
  • There were 29 males and two females, with ages ranging from 36 to 76 years (median = 55 years) with one palate, one lateral wall, 17 tonsil, 11 base of tongue, and one vallecula primary tumor classified as follows: T1 (n = 9, 29%), T2 (n = 15, 48.4%), T3 (n = 7, 22.6%), N0 (n = 6, 19.4%), N1 (n = 15, 48.4%), N2b (n = 10, 32.3%), and N2c (n = 1, 3.2%).
  • Twenty-two patients were treated postoperatively with adjuvant therapy (12 radiation alone and 12 combined radiation and chemotherapy).
  • CONCLUSIONS: SND after TORS resection of primary OPSCC enables the use of selective and deintensified adjuvant therapy to reduce regional recurrence rates.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Endoscopy. Neck Dissection / instrumentation. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Robotics / instrumentation
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prospective Studies. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20717944.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • Multivariate analyses stratified by primary site revealed that tumor volume significantly influenced local control for patients with cancers of the supraglottis (p =.0220) and glottis (p =.0042) but not for those with lesions of the tonsillar fossa/posterior tonsillar pillar (p =.0892), base of tongue (p =.9493), anterior tonsillar pillar/soft palate (p =.5909), and hypopharynx (p =.2282).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Pradier O, Christiansen H, Ambrosch P, Kron M, Schmidberger H, Hess CF: A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature. ORL J Otorhinolaryngol Relat Spec; 2004;66(6):325-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature.
  • BACKGROUND: Radiotherapy is often the primary treatment for advanced head and neck cancer, but the rates of locoregional recurrence are high and survival is poor.
  • The purpose of this study was to evaluate the efficacy and toxicity of split-course radiotherapy combined with concurrent carboplatin chemotherapy after long-term follow-up.
  • PATIENTS AND METHODS: From August 1987 to May 1994, 66 patients (54 males, 12 females, mean age 58 years) with advanced inoperable oropharynx cancer were treated at the University of Göttingen, Göttingen, Germany.
  • Tumour localization in the oropharynx was: tonsil (n = 33), base of tongue (n = 28), soft palate (n = 2) and posterior pharyngeal wall (n = 3).
  • A total radiation dose of 5,670 cGy was applied in 6 weeks as a split-course regimen (2 x 2.1 Gy/day, 4 times a week, weeks 1 and 2 and weeks 5 and 6).
  • Concomitant carboplatin chemotherapy was given each radiotherapy day before irradiation (50 mg/m(2)).
  • Therapy was tolerated moderately (19% grade 3 skin reaction, 26% grade 3 mucositis, 23% grade 3 xerostomia, 20% grade 3 leucopenia, 8% grade 3 thrombopenia and 25% grade 3 anaemia).
  • CONCLUSION: Split-course radiotherapy and concomitant carboplatin chemotherapy can be carried out in inoperable head and neck cancer without severe toxicity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15668532.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  • [Number-of-references] 46
  •  go-up   go-down


20. Watanabe A, Taniguchi M: [A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy]. Gan To Kagaku Ryoho; 2005 Jan;32(1):65-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
  • We encountered an oropharyngeal cancer patient with multiple bone metastases from prostate cancer who achieved a partial response to 3 cycles of combination chemotherapy including docetaxel, ifosfamide and cisplatin (DIP).
  • A 72-year-old man was found to have advanced oropharyngeal cancer during hormonal treatment of bone metastases from prostate cancer.
  • Combination chemotherapy was initiated with DIP.
  • After chemotherapy, computed tomography revealed no residual tumor at the oropharyngeal region, but a small ulcer was seen at the base of the tongue by laryngopharyngoscopy.
  • During chemotherapy the patient could take oral meals because of no stomatitis.
  • After chemotherapy the patient received radiation therapy (60 Gy/30 f).
  • The oropharyngeal cancer disappeared completely after radiotherapy.
  • It is suggested that combination chemotherapy with DIP is a potential new treatment modality for advanced head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Oropharyngeal Neoplasms / drug therapy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Infusions, Intravenous. Male. Quality of Life. Taxoids / administration & dosage


21. Cmelak AJ, Murphy BA, Burkey B, Douglas S, Shyr Y, Netterville J: Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck; 2007 Apr;29(4):315-24
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
  • BACKGROUND: The optimal drug schedule and sequencing of chemotherapy and radiation for organ preservation in head and neck cancer has yet to be determined.
  • We undertook a phase II trial of a taxane-based induction chemotherapy (ICT) followed by a taxane-based concurrent chemoradiation (CCR) regimen in patients with resectable stage III or IV disease to determine the feasibility, toxicity, and overall efficacy.
  • METHODS: Forty-four patients with laryngeal or tongue base carcinomas were enrolled.
  • All patients received 3 cycles of chemotherapy with paclitaxel 175 mg/m(2) and carboplatin AUC (area under the curve) 6-7.5 over 30 minutes on days 1, 22, and 43.
  • Responding patients went on to receive radiation (70 Gy/7 weeks) with cisplatin 75 mg/m(2) IV on days 1, 22, and 43 and weekly paclitaxel 30 mg/m(2) IV (n = 22).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Paclitaxel / therapeutic use. Tongue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17252600.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T: A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):783-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
  • STUDY DESIGN: This study included 92 patients who were treated by this combination therapy between May 1999 and December 2004.
  • Primary tumor sites included the tongue in 73 patients, base of the tongue in 6 patients, floor of mouth in 4 patients, buccal mucosa in 4 patients, and other sites in 5 patients.
  • In 4 patients, the catheter fell out of the selected artery during treatment.
  • CONCLUSION: This selective intra-arterial method will be an important modality for advanced tongue cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Radiography, Interventional / methods. Tongue Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206406.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A: Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1365-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach.
  • PURPOSE: To review the outcomes of a prospective management approach using ipsilateral neck radiotherapy in the treatment of node-positive squamous cell carcinoma of the tonsil with a well-lateralized primary lesion.
  • METHODS AND MATERIALS: Between August 2003 and June 2007, 20 patients who presented with squamous cell carcinoma of the tonsil, without involvement of the base of the tongue or midline soft palate, and with Stage N1-N2b disease were prospectively treated with radiotherapy to the primary site and ipsilateral neck.
  • In addition, 18 patients received concurrent chemotherapy.
  • Acute and late toxicity were prospectively evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3, and Radiation Therapy Oncology Group criteria.
  • Late Radiation Therapy Oncology Group grade 2 xerostomia occurred in 1 patient (5%).
  • CONCLUSION: In carefully selected patients with node-positive, lateralized tonsillar cancer, treatment of the ipsilateral neck and primary site does not appear to increase the risk of contralateral nodal failure and reduces late morbidity compared with historical controls.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / radiotherapy. Male. Middle Aged. Neck. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168295.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Goldstein NE, Genden E, Morrison RS: Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle". JAMA; 2008 Apr 16;299(15):1818-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle".
  • Head and neck cancers constitute a diverse group of diseases including malignancies of the oral cavity, oropharynx, larynx, sinuses, and skull base.
  • Treatment of these cancers includes a combination of surgical resection, chemotherapy, and radiation.
  • Due to both the patterns of disease recurrence and the adverse effects of treatments, patients with head and neck cancer often have a complex and prolonged course of illness that is marked by periods of freedom from disease and symptoms interspersed with bouts of serious illness, debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia.
  • Thus, management of this disease is best provided by an interdisciplinary team that includes individuals from the disciplines of otolaryngology, palliative care, radiation oncology, oncology, nutrition, speech, and physical and occupational therapy.
  • Using the case of Mr K, we describe the symptoms encountered by patients with head and neck cancer and suggest options for management.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2008 Jun 11;299(22):2679 [18544727.001]
  • (PMID = 18413876.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / K23AG025933; United States / NIA NIH HHS / AG / K24AG22345
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Schwartz DL, Hutcheson K, Barringer D, Tucker SL, Kies M, Holsinger FC, Ang KK, Morrison WH, Rosenthal DI, Garden AS, Dong L, Lewin JS: Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Dec 1;78(5):1356-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate long-term swallowing function in oropharyngeal cancer patients treated with intensity-modulated radiotherapy (IMRT), and to identify novel dose-limiting criteria predictive for dysphagia.
  • METHODS AND MATERIALS: Thirty-one patients with Stage IV oropharyngeal squamous carcinoma enrolled on a Phase II trial were prospectively evaluated by modified barium swallow studies at baseline, and 6, 12, and 24 months post-IMRT treatment.
  • Candidate dysphagia-associated organs at risk were retrospectively contoured into original treatment plans.
  • Twenty-one (68%) cases were base of tongue and 10 (32%) were tonsil.
  • Thirteen patients (42%) received concurrent chemotherapy during IMRT.
  • Mean dose to glottic larynx for the cohort was limited to 18 Gy (range, 6-39 Gy) by matching IMRT to conventional low-neck fields.

  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):695-704 [11395238.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6 [11448365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8 [12007937.001]
  • [Cites] Head Neck. 2002 Jun;24(6):555-65 [12112553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1174-84 [12128118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1219-30 [14630255.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1000-5 [15978743.001]
  • [Cites] Radiother Oncol. 2006 Sep;80(3):302-6 [16890314.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98 [17560051.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1813-20 [17546592.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95 [18086974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1695-709 [18486742.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3770-6 [18669465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):568-74 [18793959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8 [18468812.001]
  • [Cites] Head Neck. 2009 May;31(5):611-7 [19107949.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2294-301 [8635098.001]
  • [Cites] Head Neck. 2003 Dec;25(12):1034-41 [14648862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1072-82 [15001247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1100-3 [15381598.001]
  • [Cites] J Speech Hear Res. 1994 Apr;37(2):314-25 [8028312.001]
  • [Cites] Dysphagia. 1996 Spring;11(2):93-8 [8721066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):721-30 [8948358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):83-92 [9588921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • (PMID = 20646872.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA132281; United States / NCI NIH HHS / CA / CA132281
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS575664; NLM/ PMC4034521
  •  go-up   go-down


26. Beri R, Rosen FR, Pacini MJ, Desai SR: Severe dermatologic reactions at multiple sites after paclitaxel administration. Ann Pharmacother; 2004 Feb;38(2):238-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 53-year-old white male with cancer of the base of the tongue was treated with paclitaxel 100 mg/m2 infused over 3 hours and carboplatin dosed at an AUC of 6 mg/mL x min infused over 30 minutes via a peripheral vein on the left arm.
  • After 4 doses of paclitaxel, the patient developed erythematous patches on both forearms and both thighs.
  • The lesions on the left arm worsened into a necrotic ulcer, exposing underlying tissues.
  • Our patient had dermatologic toxicity at the infusion site, as well as at multiple other sites, that developed about 6 weeks after the first paclitaxel infusion.
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Humans. Male. Middle Aged. Tongue Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14742758.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Milano MT, Vokes EE, Kao J, Jackson W, List MA, Stenson KM, Witt ME, Dekker A, MacCracken E, Garofalo MC, Chmura SJ, Weichselbaum RR, Haraf DJ: Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol; 2006 May;28(5):1141-51
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
  • We review our recent experience with intensity-modulated radiation therapy (IMRT) and conventional three-dimensional radiation therapy (C3DRT) in advanced head and neck cancer.
  • Sixty-nine patients with Stage IV head and neck cancer (and stage III base of tongue and hypopharynx) enrolled in a Phase II study of definitive chemoradiation; 20 received all or part of their radiation with IMRT.
  • Six weekly doses of induction carboplatin (AUC=2) and paclitaxel (135 mg/m2) were followed by alternating weekly chemoradiation to 75 Gy with 1.5 Gy BID fractions, concurrent with paclitaxel (100 mg/m2/week), 5-fluorouracil (600 mg/m2/d) and hydroxyurea (500 mg PO BID).
  • Two consecutive cohorts enrolled, differing in radiation scheme: 75 Gy to gross disease in both, 60 or 54 Gy to first echelon lymphatics and 45 or 39 Gy to second echelon lymphatics.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596230.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NIDCR NIH HHS / DE / P50 DE11921-04
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Rohde S, Turowski B, Berkefeld J, Kovács AF: [Clinical and histopathological results after local chemoembolization of oral and oropharyngeal carcinoma--comparison with intraarterial chemoperfusion]. Rofo; 2006 Oct;178(10):979-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Klinische und histopathologische Ergebnisse nach lokaler Chemoembolisation oraler und oropharyngealer Karzinome--Vergleich mit intraarterieller Chemoperfusion.
  • PURPOSE: Retrospective analysis of clinical and histopathological results after neoadjuvant intraarterial chemoembolization (iaCE) as compared to intraarterial chemoperfusion (iaCP) in patients with oral and oropharyngeal squamous cell cancer (SCC).
  • The decision for iaCE or iaCP was made individually for each patient based on tumor localization and expected vascular supply.
  • Four weeks after local chemotherapy, the treatment response was evaluated according (1) to WHO criteria and (2) to histopathological TNM-grading after tumor resection.
  • RESULTS: The overall treatment response was 72.5 % after iaCE and 47 % after iaCP (p < 0.001).
  • Local side effects were significantly more frequent after iaCE than after iaCP (p < 0.001), especially in obese patients with extended carcinoma of the oral floor or the tongue base.
  • However, in view of the higher risk of regional complications, indication for iaCE should be considered cautiously and its application should be limited to small tumors of the oral floor and the oral tongue.
  • [MeSH-major] Chemoembolization, Therapeutic / methods. Cisplatin / administration & dosage. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Female. Germany / epidemiology. Humans. Injections, Intra-Arterial. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rofo. 2006 Dec;178(12):1266. Kovács, A [corrected to Kovács, A F]
  • (PMID = 17021977.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Indications for image-guided biopsies are preverterbal fluid-collections, spinal and paraspinal inflammations and abscesses, deep cervical malignancies, vertebral body, and skull base tumors.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Examples are a carcinoma of the alveolar ridge, a squamous cell carcinoma of the floor of the mouth, and a nasopharyngeal lymphoepithelioma.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement